We devised a diagnostic approach based on screening plasma for an Aspergillus antigen with use of a sandwich enzyme-linked immunosorbent assay (ELISA), thoracic computed tomographic scanning, and radionuclide imaging for managing patients at risk for invasive aspergillosis. We used a decision analytic model to compare this alternative strategy with the conventional strategy, which relies only on the presence of clinical symptoms, persistent fever, and chest roentgenographic findings. Use of the alternative strategy reduced the number of patients who would receive antifungal treatment empirically, but this strategy was more expensive. The specificity of the sandwich ELISA had a significant impact on cost, but the sensitivity did not. A 13% prevalence of infection resulted in equal costs for both strategies. As much as 43.3% of the patients treated empirically could be given liposomal amphotericin B (L-AmB) before the conventional strategy became the most expensive. The costs of the alternative strategy were less than those of the conventional strategy when >5.3% of all patients, irrespective of strategy, were treated with L-AmB.
Invasive pulmonary aspergillosis is a life-threatening comtericin B colloid dispersion (Amphocil, Zeneca Farma, Ridplication of intensive chemotherapy for malignancies, chronic treatment with high dose corticosteroids, transplantation, and AIDS. Treating this infection as early as possible is one of the prerequisites for a favorable outcome [1] , but since 110 reliable means of early diagnosis exists, it has become commonplace derkerk, the Netherlands), are available and are being used increasingly for treating invasive aspergillosis because they induce fewer side effects than occur with the same dose of DC-AmB. Although equal or improved efficacy of lipid formu lations of amphotericin B in treating invasive aspergillosis has to treat patients at high risk empirically with amphotericin not been proven, all the studies to date have shown that lipid formulations of amphotericin B are at least as effective as DC-AmB, even in those patients who did not respond [5] [6] [7] . Moreover, clinical trials are ongoing to establish the efficacy alone [3, 4] , even though the desoxycholate formulation of of lipid formulations of amphotericin B as empirical therapy for B when there is the slightest clinical suspicion of invasive aspergillosis [2] . As many as 68% of neutropenic patients will receive amphotericin B empirically, often for persistent fever amphotericin B (DC-AmB; Fungizone, Bristol Myers Squibb, Woerden, the Netherlands) is associated with adverse drug reactions such as fever, rigors, and impaired renal function. In addition, the incidence of disease for most groups at risk is as 10%. Therefore, alternative strategies are needed for the early recognition of invasive aspergillosis to allow better selection of patients who need treatment, while reducing the number of who are intolerant of DC-AmB or for managing progressive patients who are exposed unnecessarily to these drugs and their disease despite treatment with the desoxycholate formulation of the polyene [5] . Even if desirable, empirical treatment with In addition, better selection of patients who require treatment L-AmB is simply not feasible since resources for health care are for invasive aspergillosis will also help to contain the cost of finite and there is increasing pressure to contain costs despite an fever and neutropenia and as first-line therapy for documented aspergillosis [5] . However, the cost of treatment with these formulations is high. L-AmB is as much as 40 times more expensive than DC-AmB and is only considered for managing invasive asper gillosis in patients with impaired renal function or in those treatment when novel and expensive drugs are used. For in stance, lipid formulations of amphotericin B, such as liposomal amphotericin B (L-AmB; Ambisome, Nexstar, St. Odilienberg, the Netherlands), amphotericin B lipid-complex (Abelcet, The Liposome Company, Reeuwijk, the Netherlands), and ampho-ical Miinexorable rise in demand.
To address this issue we devised a diagnostic approach (alter native strategy) that incorporates Aspergillus antigen detection, high resolution CT scanning, and radionuclide imaging with indium-111-labeled human IgG ("'in-IgG). Each of these pro cedures have been shown to contribute to establishing the diag nosis of invasive aspergillosis, but the diagnostic value o f an approach in which the tests and procedures are combined is unknown. The Aspergillus antigen galactomannan can be de tected in plasma or serum samples from patients with invasive aspergillosis by using a commercially available sandwich ELISA (Platelia Aspergillus, Sanofi Diagnostics Pasteur, Marnes-La-Coquette, France) [8] . This assay has been found to possess a sensitivity of 67% -100% and a specificity of each test result, together with the costs of the diagnostic tests and treatments, were estimated and incorporated into the deci sion tree by using the software program DATA version 2.6 (TreeAge Software, Williamstown, MA). After the path probaadditional costs of the diagnostic tests included in the alterna tive strategy were outweighed by any savings resulting from the avoidance of unnecessary treatment. Since different values for both sensitivity and specificity of the sandwich ELISA have bilities of each branch of the tree and the expected costs of been reported [9] [10] [11] [12] [13] , the impact of varying the performance diagnosis and treatment per patient were calculated for each strategy, sensitivity analysis was performed.
Primary calculations on the costs of both strategies were based on treatment with DC-AmB to determine whether the Table 1 . Baseline values and ranges of variables and test character istics used to construct the decision tree for comparing two strategies for managing invasive aspergillosis.
Reference: Variable
Baseline value (%)
Prevalence of invasive aspergillosis characteristics of the sandwich ELISA on the positive and negative predictive values and the expected costs of the alterna tive strategy was determined by varying the sensitivity and specificity with use of values from the literature and the hypo thetical values of 50% and 99%, given a 6% prevalence rate of infection. Besides this, we used the variables prevalence of infection (baseline value, 6%), the probability that a patient would receive empirical treatment with DC-AmB (baseline value, 24%), and the costs of the sandwich ELISA (baseline value, $ 10) in the sensitivity analysis. Treatment with L-AmB. The impact of the availability of L-AmB was evaluated by incorporating three different possibil ities of using this expensive drug in the model. First, we as sumed that all patients with invasive aspergillosis diagnosed by the alternative strategy would be treated with L-AmB and that all patients whose cases were diagnosed by the conven tional strategy would be treated with DC-AmB. Second, we analyzed the situation in which all patients with invasive asper gillosis diagnosed by the alternative strategy would be treated with L-AmB and that a varying proportion of those cases diag nosed by the conventional strategy would also be treated with L-AmB. Last, we assumed that the same proportion o f patients whose cases were diagnosed according to both strategies would receive L-AmB. In addition, for the second and third scenarios, we calculated the threshold at which the expected costs were equal for both strategies. We also performed a two-way sensi tivity analysis to examine the relationship between the propormained high (table 3) . Decreasing the specificity of the test from 99% to 50%) nearly doubled the because the number of false-positive to the more frequent performance of CT scanning. By contrast, lowering the sensitivity of the ELISA from 99% to 50% had only a marginal effect on the expected costs per patient, reduc tion of patients treated with L-AmB and the prevalence of ing them from $480 per patient to $476 per patient when the invasive aspergillosis.
Results
Probability o f receiving treatment. The probability of re ceiving antifungal treatment as a result of the conventional strategy was .24 (figure 1; path probabilities, .06 + .18), while the probability of receiving antifungal treatment unnecessarily was .18. The probability of receiving antifungal treatment as a result of the alternative strategy was .073 (figure 1; path .054 + .005 + .003 + .003 + .008 + .000), with 74% of these cases identified by antigen detection and confirmed by CT scanning. The probability of a patient incor rectly receiving treatment was .013, whereas only one of every 1,000 patients would incorrectly not receive treatment as a result of a positive ELISA result unconfirmed by imaging. The expected costs of diagnosis by the conventional and alternative strategies were estimated respectively to be $167 per patient and $463 per patient, res My, and those of treatment were $156 per patient and $63 per patient, respectively. Thus, the of $93 per patient, accrued by ïs on t
did not compensate for the extra investment in the diagnostic tests and procedures ($296 per patient). Under baseline assumptions, an overall investment of $203 per patient would be required to implement the alternative strategy.
Test characteristics. As expected, the positive value for the conventional strategy was low (25%), and the negative predictive value was high (100%). Irrespective of the level of sensitivity, the positive predictive value o f the alternaspecificity was 99%, and from $922 per patient to $919 per patient when the specificity was 50%. This effect is due to the fact that patients with a false diagnosis of freedom from disease will ultimately develop clinical signs and symptoms consistent with invasive aspergillosis and will still undergo CT scanning.
Sensitivity analyses. When the baseline values for the sen-* sitivity and specificity of the sandwich ELISA were used, the alternative strategy became less expensive than the conven tional strategy once the prevalence of invasive aspergillosis exceeded 13% (figure 2), and even when the worst test perfor mance values were used, to 15,1%. Similarly, the a prevalence of 11.5% increased only slightly dropped only marginally to the best test performance values of sensitivity and specificity of the sandwich ELISA At a prevalence rate of 13%, the probability of patients having invasive aspergillosis but wrongly not receiving treatment re-. Given baseline values mained at i 1 for the performance 3 alternative strategy, strati'« more expensive than that a patient would be treated exceeded 48.8%.
were equal costs per patient of the the cost of the sandwich ELISA was $3.30.
Treatment with L-
The expected costs of the alterna tive strategy were estimated to be $3,096 per patient, assuming that each patient invasive tre This approach was always be more ex pensive than the conventional strategy and treatment with not be identified for the prev-DC-AmB, since thresholds c alence of infection, for the probability that a patient would tive strategy declined from 88% to 54% as the specificity o f receive empirical treatment, or for the costs of the sandwich the ELISA decreased, but the negative predictive value re-ELISA. was available to all patients, CID 1997;25 (November) 14-fold from .18 to .013 by using the alternative as a result of the conventional strategy could be treated with strategy we propose. We were also encouraged by the finding this formulation before the alternative strategy became less that the probability of withholding treatment incorrectly was expensive. Assuming that only a proportion of patients were treated with L-AmB, irrespective of the diagnostic strategy likely to be very low (.001), although not zero. However, we assumed that no cases would go undiagnosed by the convenused, the one-way sensitivity analysis showed that the expected tional strategy, which is unlikely to be the case, since invasive costs of the alternative strategy were only lower than those of aspergillosis only becomes apparent at autopsy for the majority the conventional strategy when >5.3% of all patients given of patients [20] . antifungal therapy were treated with L-AmB. The two-way
The strategy we propose requires physicians to withhold sensitivity analysis (figure 3) showed an inverse relationship treatment from patients who would otherwise have received between the proportion of patients treated with L-AmB therapy empirically. Typically, these patients would be febrile for invasive aspergillosis and the prevalence of invasive asperand neutropenic, but galactomannan would not be detected in blood samples, and CT scans would not show lesions consistent with invasive aspergillosis. Of course, other fungal pathogens may cause clinical signs and symptoms that are difficult to differentiate from invasive aspergillosis; nevertheless, the fear The increasing incidence of invasive aspergillosis [20] , the that patients may die of invasive aspergillosis compels many
D iscussion
high morbidity and mortality associated with the infection, and the costs of treatment with novel antifungal agents underscore to mammine t the need for alternative The decision tree we constructed can be used as a model to predict the outcome and expected costs of implementing strate gies for diagnosing or treating invasive aspergillosis in patients physicians to begin treatment empirically after 3 -5 days of persistent fever that is refractory to antibacterial therapy, even in the absence of any pulmonary or sinus abnormalities. Thus, as many as two-thirds of all neutropenic patients are given empirical antifungal therapy [3, 4] .
Clearly, the withholding of treatment will be difficult to achieve ?al treatment, rather than with hematologic malignancies. We patients who would receive survival, as the measure of outcome since is more commonplace and usefu l, whereas the mortality associ ated with invasive aspergillosis depends not only on antifungal treatment but also on whether remission from the underlying disease is achieved [ I ] . However, we acknowledge that the baseline values necessary for decision analysis are likely to proportion of in such circumstances because the morbidity associated with DC differ between different institutions and depend on the nature and type of tests and procedures used to diagnose invasive aspergillosis, the prevalence of the disease, and, more im portant, the guidelines governing the institution of empirical antifungal therapy. Under the assumed baseline values obtained at our hospital, the probability of receiving treatment unnecessarily could be AmB therapy is regarded as less harmful than is the withholding of treatment from a patient with disease. Furthermore, when other less toxic antifungal agents are made available, the threshold for treating patients empirically will be lower still, with only the high cost of novel antifungal agents and the finiteness of resources providing disincentives to using these drugs empirically. The eval uation of alternative strategies for managing invasive aspergillosis is therefore imperative if we are to define the place of new antifun gal agents and control their use.
The baseline values for the performance of the sandwich ELISA were based on the results of a prospective study of children during treatment for a hematologic malignancy [10] . However, false-positive ELISA results have been reported to occur within 30 days after bone marrow transplantation [11] of treatment with this formulation even though they were ex pected to be high because a larger number of cases diagnosed by the conventional strategy would receive treatment. As a consequence, all calculated expected costs were a conservative estimate of the actual costs. Nevertheless, the alternative strat egy we propose will become less expensive than the conven tional strategy if >5.3% of the treated patients are treated with L-AmB and it will become even less expensive if it proves in circumstances where the majority of patients with ic malignancies currently receive gal treatment ;Uso high among these 5, so se cases of invasive as by using the alternative strategy may the most from being given first-line treatment with LAmB. However, the costs o f treating all such patients with LAmB will be high; thus a comparative study of L-AmB and DC-AmB is still required to determine the feasibility of this Prevalence of invasive aspergillosis (%) Figure 2 . One-way sensitivity analysis of the decision tree to deter mine the effect of the prevalence of invasive aspergillosis on the expected costs per patient. The prevalence of aspergillosis is varied in the sensitivity analysis which results in lines indicating the expected costs of each strategy. Where the lines of the strategies intersect (prevalence of 13%, given baseline test performance), this intersection defines a threshold point. If the prevalence of invasive aspergillosis is below the threshold, the conventional strategy is optimal; if this prevalence is above the threshold, then the alternative strategy is optimal. Baseline values for the sensitivity and specificity of ELISA in the alternative strategy are 100% and 94%, respectively. The worst case values, 67% for sensitivity and 84% for specificity, result in a threshold of 11.5%; in the best case these values are both 100%, 
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Prevalence of invasive aspergillosis (%) specificity of the sandwich ELISA [21] . However, since Figure 3 , Two-way sensitivity analysis of the decision tree to detersequential tests and procedures are used in the alternative stratto diagnose invasive aspergillosis, the impact o f a less sensitive and specific ELISA on the positive and negative premine fleet of the prevalence of invasive aspergillosis and the percentage of treated patients who received liposomal amphotericin B (L-AmB) in both strategies according to the expected costs per patient. As in figure 2 , the results for the worst-casc and hest-case dictive values of the strategy as a whole is likely to be negligivalues of sensitivity and specificity, as well as baseline values for ble. Nevertheless, the total costs per patient will increase consensitivity and specificity of ELLSA, are given. The curves indicate siderably, especially if the specificity proves low. In addition the combinations of values for the prevalence of aspergillosis and percentage of patients treated with L-AmB for which the expected costs of the two strategies are equal. Any coordinate to the left of o f the sandwich ELISA as a screening test for galactomannan the curves favors the conventional strategy, whereas any coordinate may also allow for the diagnosis to be made at an early stage to the right of the curves f avors the alternative strategy. There is an to better selection of patients for i
, at least for some patients [7] [8] [9] .
ventional strategy current conexpensive per patient than 2 strategy when patients were treated with inverse relationship between prevalence of aspergillosis and percent age of patients treated with L-AmB. Thus, with our current preva- 
